MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice

European Journal of Pharmacology

Volumn 691, Issue 1-3, 2012, Pages 69-76

  Kim, Ha Neui ^a   Lee, Jong Ho ^a   Jin, Won Jong ^a   Ko, Sungjin ^a   Jung, Kyoungsuk ^a   Ha, Hyunil ^b   Lee, Zang Hee ^a  

^a Seoul National University   (South Korea)

^b Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Bone destruction; c Fos; HDAC (histone deacetylase); MS 275; Osteoclast; RANKL (receptor activator of NF B ligand)

Indexed keywords

ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE MARROW CELL; CALVARIA; CELL ACTIVATION; CELL COUNT; CELL DIFFERENTIATION; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

ANIMALS; BENZAMIDES; BONE MARROW CELLS; BONE RESORPTION; CELL DIFFERENTIATION; COCULTURE TECHNIQUES; DOWN-REGULATION; HISTONE DEACETYLASE INHIBITORS; INTERLEUKIN-1; MALE; MICE; MICE, INBRED ICR; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PROTO-ONCOGENE PROTEINS C-FOS; PYRIDINES; RANK LIGAND;

EID: 84865023848     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.07.034     Document Type: Article

References (41)

1. S.B. Abramson, and A. Amin Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage Rheumatology 41 2002 972 980
2. J.E. Bolden, M.J. Peart, and R.W. Johnstone Anticancer activities of histone deacetylase inhibitors Nat. Rev. Drug Discovery 5 2006 769 784 (Pubitemid 44348499)
3. W.J. Boyle, W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 2003 337 342 (Pubitemid 40852708)
4. J.E. Bradner, N. West, M.L. Grachan, E.F. Greenberg, S.J. Haqqarty, T. Warnow, and R. Mazitschek Chemical phylogenetics of histone deacetylases Nat. Chem. Biol. 6 2010 238 243
5. M.D. Cantley, P.M. Bartold, V. Marino, D.P. Fairlie, G.T. Le, A.J. Lucke, and D.R. Haynes Histone deacetylase inhibitors and periodontal bone loss J. Periodontal Res. 46 2011 697 703
6. M.D. Cantley, D.P. Fairlie, P.M. Bartold, K.D. Rainsford, G.T. Le, A.J. Lucke, C.A. Holding, and D.R. Haynes Inhibitors of histone deacetylases in Class I and Class II suppress human osteoclasts in vitro J. Cell. Physiol. 226 2011 3233 3241
7. H.H. Cho, H.T. Park, Y.J. Kim, Y.C. Bae, K.T. Suh, and J.S. Jung Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors J. Cell. Biochem. 96 2005 533 542 (Pubitemid 41504651)
8. Q.Y. Choo, P.C. Ho, Y. Tanaka, and H.S. Lin Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells Rheumatology (Oxford) 49 2010 1447 1460
9. A.E. Grigoriadis, Z.Q. Wang, M.G. Cecchini, W. Hofstetter, R. Felix, H.A. Fleisch, and E.F. Wagner c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling Science 266 1994 443 448
10. H. Ha, J.H. Lee, H.N. Kim, H.M. Kim, H.B. Kwak, S. Lee, H.H. Kim, and Z.H. Lee α-Lipoic acid inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis J. Immunol. 176 2006 111 117 (Pubitemid 43023254)
11. C.A. Hazzalin, and L.C. Mahadevan Dynamic acetylation of all lysine 4-methylated histone H3 in the mouse nucleus: analysis at c-fos and c-jun PLoS Biol. 3 2005 2111 2126
12. H. Huang, E.J. Chang, J. Ryu, Z.H. Lee, Y. Lee, and H.H. Kim Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway Biochem. Biophys. Res. Commun. 351 2006 99 105 (Pubitemid 44635412)
13. D.E. Hughes, K.R. Wright, H.L. Uy, A. Sasaki, T. Yoneda, G.D. Roodman, G.R. Mundy, and B.F. Boyce Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo J. Bone Miner. Res. 10 1995 1478 1487
14. E.J. Jeon, K.Y. Lee, N.S. Choi, M.H. Lee, H.N. Kim, Y.H. Jin, H.M. Ryoo, J.Y. Choi, M. Yoshida, N. Nishino, B.C. Oh, K.S. Lee, Y.H. Lee, and S.C. Bae Bone morphogenetic protein-2 stimulates Runx2 acetylation J. Biol. Chem. 281 2006 16502 16511
15. H.N. Kim, H. Ha, J.H. Lee, K. Jung, D. Yang, K.M. Woo, and Z.H. Lee Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANK Eur. J. Pharmacol. 623 2009 22 29
16. H.N. Kim, J.H. Lee, S.C. Bae, H.M. Ryoo, H.H. Kim, H. Ha, and Z.H. Lee Histone deacetylase inhibitor MS-275 stimulates bone formation in part by enhancing Dhx36-mediated TNAP transcription J. Bone Miner. Res. 26 2011 2161 2173
17. H.J. Kim, Y. Lee, E.J. Chang, H.M. Kim, S.P. Hong, Z.H. Lee, J. Ryu, and H.H. Kim Suppression of osteoclastogenesis by N,N-dimethyl-D-erythro- sphingosine: a sphingosine kinase inhibition-independent action Mol. Pharmacol. 72 2007 418 428 (Pubitemid 47124122)
18. Y.Y. Kong, H. Yoshida, I. Sarosi, H.L. Tan, E. Timms, C. Capparelli, S. Morony, A.J. Oliveira-dos-Santos, G. Van, A. Itie, W. Khoo, A. Wakeham, C.R. Dunstan, D.L. Lacey, T.W. Mak, W.J. Boyle, and J.M. Penninger OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 397 1999 315 323
19. D.L. Lacey, E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy, C. Capparelli, A. Eli, Y.X. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi, J. Guo, J. Delaney, and W.J. Boyle Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 1998 165 176 (Pubitemid 28180851)
20. J.H. Lee, H. Jin, H.E. Shim, H.N. Kim, H. Ha, and Z.H. Lee Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-κB signal Mol. Pharmacol. 77 2010 17 25
21. J.H. Lee, H.N. Kim, D. Yang, K. Jung, H.M. Kim, H.H. Kim, H. Ha, and Z.H. Lee Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling J. Biol. Chem. 284 2009 13725 13734
22. H.S. Lin, C.Y. Hu, H.Y. Chan, Y.Y. Liew, H.P. Huang, L. Lepescheux, E. Bastianelli, R. Baron, G. Rawadi, and P. Clément-Lacroix Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents Br. J. Pharmacol. 150 2007 862 872 (Pubitemid 46536628)
23. J.A. Lorenzo, A. Naprta, Y. Rao, C. Alander, M. Glaccum, M. Widmer, G. Gronowicz, J. Kalinowski, and C.C. Pilbeam Mice lacking the type I interleukin-1 receptor do not loss bone mass after ovariectomy Endocrinology 139 1998 3022 3025 (Pubitemid 28512417)
24. K. Matsuo, D.L. Galson, C. Zhao, L. Peng, C. Laplace, K.Z.Q. Wang, M.A. Bachler, H. Amano, H. Aburatani, H. Ishikawa, and E.F. Wagner Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos J. Biol. Chem. 279 2004 26475 26480 (Pubitemid 38798801)
25. M.E. McGee-Lawrence, A.L. McCleary-Wheeler, F.J. Secreto, D.F. Razidlo, M. Zhang, B.A. Stensqard, X. Li, G.S. Stein, J.B. Lian, and J.J. Westendorff Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts Bone 48 2011 1117 1126
26. M.E. McGee-Lawrence, and J.J. Westendorf Histone deacetylases in skeletal development and bone mass maintenance Gene 474 2011 1 11
27. T. Nakamura, T. Kukita, T. Shobuike, K. Nagata, Z. Wu, K. Ogawa, T. Hotokebuchi, O. Kohashi, and A. Kukita Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production J. Immunol. 175 2005 5809 5816 (Pubitemid 41508065)
28. L.S. Nissen-Meyer, S. Svalheim, E. Tauboll, S. Reppe, T. Lekva, L.B. Solberg, G. Melhus, F.P. Reinholt, L. Gjerstad, and R. Jemtland Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism Epilepsia 48 2007 1850 1860 (Pubitemid 47537449)
29. L. Pham, B. Kaiser, A. Romsa, T. Schwarz, R. Gopalakrishnan, E.D. Jensen, and K.C. Mansky HDAC3 and HDAC7 have opposite effects on osteoclast differentiation J. Biol. Chem. 286 2011 12056 12065
30. T.D. Rachner, S. Khosla, and L.C. Hofbauer Osteoporosis: now and the future Lancet 377 2011 1276 1287
31. M.M. Rahman, A. Kukita, T. Kukita, T. Shobuike, T. Nakamura, and O. Kohashi Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages Blood 101 2003 3451 3459 (Pubitemid 36868944)
32. M.L. Schmitz, I. Mattioli, H. Buss, and M. Kracht NF-kappaB: a multifaceted transcription factor regulated at several levels ChemBioChem 5 2004 1348 1358 (Pubitemid 39371504)
33. T.M. Schroeder, and J.J. Westendorf Histone deacetylase inhibitors promote osteoblast maturation J. Bone Miner. Res. 20 2005 2254 2263 (Pubitemid 41698788)
34. S.M. Senn, S. Kantor, I.J. Poulton, M.J. Morris, N.A. Sims, T.J. O'Brien, and J.D. Wark Adverse effects of valproate on bone: defining a model to investigate the pathophysiology Epilepsia 51 2010 984 993
35. T. Suda, N. Takahashi, N. Udagawa, E. Jimi, M.T. Gillespie, and T.J. Martin Modulation of osteoclast differentiation and function by the new member of the tumor necrosis factor receptor and ligand families Endocr. Rev. 20 1999 345 357 (Pubitemid 30649812)
36. Y. Takada, A. Gillenwater, H. Ichikawa, and B.B. Aggarwal Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-κB activation J. Biol. Chem. 281 2006 5612 5622 (Pubitemid 43847658)
37. H. Takayanagi, S. Kim, T. Koga, H. Nishina, M. Isshiki, H. Yoshida, A. Saiura, M. Isobe, T. Yokochi, J.I. Inoue, E.F. Wagner, T.W. Mak, T. Kodama, and T. Taniguchi Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts Dev. Cell 3 2002 889 901 (Pubitemid 35460788)
38. S. Tanaka, K. Nakamura, N. Takahasi, and T. Suda Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system Immunol. Rev. 208 2005 30 49 (Pubitemid 41746383)
39. J. Xiong, M. Onal, R.L. Jilka, R.S. Weinstein, S.C. Manolagas, and C.A. O'Brien Matrix-embedded cells control osteoclast formation Nat. Med. 17 2011 1235 1242
40. T. Yamashita, Z. Yao, F. Li, Q. Zhang, I.R. Badell, E.M. Schwarz, S. Takeshita, E.F. Wagner, M. Noda, K. Matsuo, L. Xing, and B.F. Boyce NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1 J. Biol. Chem. 282 2007 18245 18253 (Pubitemid 47100255)
41. T. Yi, J.H. Baek, H.J. Kim, M.H. Choi, S.B. Seo, H.M. Ryoo, G.S. Kim, and K.M. Woo Trichostatin A-mediated upregulation of p21(WAF1) contributes to osteoclast apoptosis Exp. Mol. Med. 39 2007 213 221 (Pubitemid 46683407)